BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 35426920)

  • 21. Prognostic impact of preoperative neutrophil-to-lymphocyte ratio after radical prostatectomy in localized prostate cancer.
    Jang WS; Cho KS; Kim KH; Yoon CY; Kang YJ; Lee JY; Ham WS; Rha KH; Hong SJ; Choi YD
    Prostate Cancer Prostatic Dis; 2016 Sep; 19(3):298-304. PubMed ID: 27349499
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Is neutrophil-to-lymphocytes ratio a clinical relevant preoperative biomarker in upper tract urothelial carcinoma? A meta-analysis of 4385 patients.
    Vartolomei MD; Kimura S; Ferro M; Vartolomei L; Foerster B; Abufaraj M; Shariat SF
    World J Urol; 2018 Jul; 36(7):1019-1029. PubMed ID: 29468284
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic value of pretreatment neutrophil-to-lymphocyte ratio in renal cell carcinoma: a systematic review and meta-analysis.
    Shao Y; Wu B; Jia W; Zhang Z; Chen Q; Wang D
    BMC Urol; 2020 Jul; 20(1):90. PubMed ID: 32631294
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The impact of neutrophil-to-lymphocyte, platelet-to-lymphocyte and haemoglobin-to-platelet ratio on localised renal cell carcinoma oncologic outcomes.
    Albisinni S; Pretot D; Al Hajj Obeid W; Aoun F; Quackels T; Peltier A; Roumeguère T
    Prog Urol; 2019; 29(8-9):423-431. PubMed ID: 31196826
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
    Diem S; Schmid S; Krapf M; Flatz L; Born D; Jochum W; Templeton AJ; Früh M
    Lung Cancer; 2017 Sep; 111():176-181. PubMed ID: 28838390
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preoperative neutrophil-lymphocyte ratio can significantly predict mortality outcomes in patients with non-muscle invasive bladder cancer undergoing transurethral resection of bladder tumor.
    Kang M; Jeong CW; Kwak C; Kim HH; Ku JH
    Oncotarget; 2017 Feb; 8(8):12891-12901. PubMed ID: 28039452
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of outcomes in inflammatory breast cancer.
    Al Jarroudi O; El Bairi K; Abda N; Zaimi A; Jaouani L; Chibani H; Afqir S
    Biomark Med; 2021 Oct; 15(14):1289-1298. PubMed ID: 34486882
    [No Abstract]   [Full Text] [Related]  

  • 28. Prognostic significance of neutrophil-to-lymphocyte ratio in HPV status era for oropharyngeal cancer.
    Fanetti G; Alterio D; Marvaso G; Gandini S; Rojas DP; Gobitti C; Minatel E; Revelant A; Caroli A; Francia CM; Alessandro O; Pepa M; Gugliandolo SG; Starzyńska A; Polesel J; Vaccher E; Cossu Rocca M; Tagliabue M; Ansarin M; Lupato V; Giacomarra V; De Paoli A; Orecchia R; Franchin G; Jereczek-Fossa BA
    Oral Dis; 2020 Oct; 26(7):1384-1392. PubMed ID: 32315470
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The utility of pretreatment systemic inflammatory response biomarkers on overall survival of cervical cancer patients stratified by clinical staging.
    Santos Thuler LC; Reis Wariss B; Nogueira-Rodrigues A; de Melo AC; Bergmann A
    Eur J Obstet Gynecol Reprod Biol; 2021 Sep; 264():281-288. PubMed ID: 34352424
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Neutrophil to lymphocyte ratio in peripheral blood: a novel independent prognostic factor in patients with head and neck squamous cell carcinoma].
    Wu F; Wu LL; Zhu LX
    Zhonghua Zhong Liu Za Zhi; 2017 Jan; 39(1):29-32. PubMed ID: 28104030
    [No Abstract]   [Full Text] [Related]  

  • 31. Baseline neutrophil-lymphocyte ratio (≥2.8) as a prognostic factor for patients with locally advanced rectal cancer undergoing neoadjuvant chemoradiation.
    Shen L; Zhang H; Liang L; Li G; Fan M; Wu Y; Zhu J; Zhang Z
    Radiat Oncol; 2014 Dec; 9():295. PubMed ID: 25518933
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
    Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
    J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic impact of the combination of neutrophil-to-lymphocyte ratio and Glasgow prognostic score in colorectal cancer: a retrospective cohort study.
    Inamoto S; Kawada K; Okamura R; Hida K; Sakai Y
    Int J Colorectal Dis; 2019 Jul; 34(7):1303-1315. PubMed ID: 31177316
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Validation of Neutrophil-to-lymphocyte Ratio in a Multi-institutional Cohort of Patients With T1G3 Non-muscle-invasive Bladder Cancer.
    Vartolomei MD; Ferro M; Cantiello F; Lucarelli G; Di Stasi S; Hurle R; Guazzoni G; Busetto GM; De Berardinis E; Damiano R; Perdona S; Verze P; La Rocca R; Borghesi M; Schiavina R; Brunocilla E; Almeida GL; Bove P; Lima E; Grimaldi G; Autorino R; Crisan N; Abu Farhan AR; Battaglia M; Serretta V; Russo GI; Morgia G; Terracciano D; Musi G; de Cobelli O; Mirone V; Shariat SF
    Clin Genitourin Cancer; 2018 Dec; 16(6):445-452. PubMed ID: 30077463
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use.
    Lorente D; Mateo J; Templeton AJ; Zafeiriou Z; Bianchini D; Ferraldeschi R; Bahl A; Shen L; Su Z; Sartor O; de Bono JS
    Ann Oncol; 2015 Apr; 26(4):750-755. PubMed ID: 25538172
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of neutrophil-to-lymphocyte ratio as a prognostic indicator in a Singapore cohort of patients with clinically localized prostate cancer treated with prostatectomy.
    Lu Y; Huang HH; Lau WKO
    World J Urol; 2020 Jan; 38(1):103-109. PubMed ID: 30953141
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of Pre-Treatment NLR and Other Hematologic Biomarkers on the Outcomes of Early-Stage Non-Small-Cell Lung Cancer Treated with Stereotactic Body Radiation Therapy.
    Aduquaye M; Dube S; Bashir B; Chowdhury A; Ahmed N; Leylek A; Kim J; Lambert P; Bucher O; Hunter W; Sivananthan G; Koul R; Rathod S
    Curr Oncol; 2022 Jan; 29(1):193-208. PubMed ID: 35049693
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pre-treatment neutrophil-to-lymphocyte ratio as predictor of adverse outcomes in patients undergoing radical cystectomy for urothelial carcinoma of the bladder.
    Hermanns T; Bhindi B; Wei Y; Yu J; Noon AP; Richard PO; Bhatt JR; Almatar A; Jewett MA; Fleshner NE; Zlotta AR; Templeton AJ; Kulkarni GS
    Br J Cancer; 2014 Jul; 111(3):444-51. PubMed ID: 24918819
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neutrophil-to-lymphocyte ratio as a prognostic marker for head and neck cancer with lung metastasis: a retrospective study.
    Yanni A; Buset T; Bouland C; Loeb I; Lechien JR; Rodriguez A; Journe F; Saussez S; Dequanter D
    Eur Arch Otorhinolaryngol; 2022 Aug; 279(8):4103-4111. PubMed ID: 35099595
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Promising role of preoperative neutrophil-to-lymphocyte ratio in patients treated with radical nephroureterectomy.
    Vartolomei MD; Mathieu R; Margulis V; Karam JA; Rouprêt M; Lucca I; Mbeutcha A; Seitz C; Karakiewicz PI; Fajkovic H; Wood CG; Weizer AZ; Raman JD; Rioux-Leclercq N; Haitel A; Bensalah K; Rink M; Briganti A; Xylinas E; Shariat SF
    World J Urol; 2017 Jan; 35(1):121-130. PubMed ID: 27209168
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.